Clinical trial · Interventional
Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia
NCT02872818CI-TRIAL-00023611completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine apoptotic signaling pathways such as Survivin, Bcl-2, Bax, c-Myc and caspase-9 expression levels in rats model with iatrogenic endometrial hyperplasia after metformin and medroxyprogesterone acetate administration.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Apoptotic Signal Pathways in Endometrial Hyperplasia | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 17β estradiol hemihydrate | Drug | — | UNRESOLVED |
| medroxyprogesterone acetate | Drug | — | UNRESOLVED |
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Control group
- description
- Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
- interventionNames
- Drug: 17β estradiol hemihydrate
- type
- ACTIVE_COMPARATOR
- label
- Metformin group
- description
- Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
- interventionNames
- Drug: 17β estradiol hemihydrate
- Drug: Metformin
- type
- ACTIVE_COMPARATOR
- label
- Medroxyprogesterone acetate group
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 8 Weeks
- Maximum age
- 10 Weeks
Show eligibility criteria text
Inclusion criteria: Forty-eight weeks old female Wistar-Albino rats, weighting between 180 and 260 g Exclusion criteria. We have no exclusion criteria because we examine drugs effects in the experimental rats
References
Publications (0)
Data not yet available
No reference posted for this study.